Peripheral T‐cell lymphomas
Copyright policy )Peripheral T‐cell lymphomas
AbstractThe treatment of peripheral T‐cell lymphomas is challenging, as they often display a severe prognosis and lack effective treatment strategies. We will try to answer three burning questions: can we differentiate the initial treatment based on the histotype and the clinical presentation of peripheral T‐cell lymphoma patients? Do we require an autologous stem cell transplantation in all patients? Is there room for improvement in the setting of relapsed and refractory disease?
Treatment Outcome, Immunoconjugates, azacitidine; brentuximab vedotin; duvelisib; golidocitinib; linperlisib; peripheral T-cell lymphomas; valemetostat, Hematopoietic Stem Cell Transplantation, Humans, Lymphoma, T-Cell, Peripheral, Prognosis, Transplantation, Autologous
Treatment Outcome, Immunoconjugates, azacitidine; brentuximab vedotin; duvelisib; golidocitinib; linperlisib; peripheral T-cell lymphomas; valemetostat, Hematopoietic Stem Cell Transplantation, Humans, Lymphoma, T-Cell, Peripheral, Prognosis, Transplantation, Autologous
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).11 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!